Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936135 | 1.00 | MAPT (0.73) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL16025066 | 1.00 | MAPT (0.73) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL28513094 | 1.00 | MAPT (0.73) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL28498890 | 1.00 | MAPT (0.73) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL23564402 | 0.85 | MAPT (1.00) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL23527228 | 0.85 | MAPT (1.00) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL15694857 | 0.85 | MAPT (0.62) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL23564629 | 0.85 | MAPT (1.00) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL2292294 | 0.85 | MAPT (0.62) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL23564320 | 0.85 | MAPT (1.00) | MAPTPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072546-A | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-113072542-A | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-2964222-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| EP-0659178-A4 | CHIRAL QUINOLONE INTERMEDIATES. | ABBOTT LAB (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0659178-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994006766-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5252747-A | Chiral quinolone intermediates | ABBOTT LABORATORIES (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | MAPT 2013/4885PDK1 274/4885PDK2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.